NLRP3 inhibitor, MCC950, reduced the rate of HT in stroke animal models, accompanied by decreased leukocyte recruitment.70, 75 The evidence indicates that inflammasome inhibiting treatment may help to liberalize the time window for thrombolytic therapy through preventing HT occurrence. Here, NLRP3 is linked to hematocrit.